Week in Review: Vivo Ventures Leads $30 Million Funding of Jingfeng Pharma
Vivo Ventures is the lead investor in a $30 million funding of Shanghai Jingfeng Pharma, a maker of sodium hyaluronate; China National Pharma Group (Sinopharm) is having M&A discussions with European life science companies; Zhongyuan Union Stem Cell Bioengineering signed a stem cell venture MOU with Cell Therapy of Wales; Pioneer Pharma of Hong Kong completed a $2.5 million investment into California-based NovaBay® Pharma; Akeso Biopharma, a new China antibody drug discovery company, began operations in Zhongshan, drawn by aggressive incentives; Lundbeck of Denmark opened a $7.6 million production plant in Tianjin for its CNS drugs; and Mindray Medical reported higher Q2 revenues that were below analysts’ estimates. More details…. Stock Symbols: (SHA: 600645) (NYSE: NBY) (CPH: LUN) (NYSE: MR) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here